Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

99mTc renal tubular function agents: current status.

D Eshima1, A R Fritzberg, A Taylor

  • 1Emory University School of Medicine, Atlanta, GA.

Seminars in Nuclear Medicine
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Proceedings of the National Academy of Sciences of the United States of America·2000
Same author

Antibody pretargeted radiotherapy: a new approach and a second chance.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1998
Same author

Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate).

Bioconjugate chemistry·1998
Same author

The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases.

Nuclear medicine and biology·1997
Same author

Biorecognition of antibodies in vivo: potential in drug targeting.

Journal of molecular recognition : JMR·1996
Same author

186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.

Cancer biotherapy & radiopharmaceuticals·1996

Technetium-99m mercaptoacetyltriglycine (99mTc MAG3) shows promise as a renal tubular function agent, offering improved imaging over iodine-131 orthoiodohippuric acid (131I OIH). However, its clearance is lower than 131I OIH, and no superior agent has been developed.

Area of Science:

  • Nuclear Medicine
  • Radiopharmaceutical Chemistry
  • Renal Physiology

Background:

  • 131I orthoiodohippuric acid (OIH) is a standard for effective renal plasma flow (EPRF) measurement.
  • Limitations of 131I OIH include poor imaging and high radiation dose.
  • 123I OIH is costly with a short shelf-life, hindering widespread use.

Purpose of the Study:

  • To develop a novel 99mTc-labeled renal tubular function agent.
  • To combine optimal 99mTc properties with the clinical information of OIH.
  • To identify a superior alternative to existing renal radiopharmaceuticals.

Main Methods:

  • Investigated diamide dithiolate (N2S2), paraaminohippuric iminodiacetic acid (PAHIDA), and triamide mercaptide (N3S) ligand systems.
  • Evaluated 99mTc mercaptoacetyltriglycine (99mTc MAG3) in animal models under various physiological conditions.

Related Experiment Videos

  • Assessed 99mTc MAG3 in normal subjects and patients.

    • Main Results:

    • 99mTc MAG3, an N3S complex, demonstrated similar behavior to 131I OIH in animal models.
    • A simple kit formulation provides high radiochemical purity for 99mTc MAG3.
    • 99mTc MAG3 exhibits excellent performance but has 50-60% plasma clearance compared to OIH.

    Conclusions:

    • 99mTc MAG3 is a promising renal tubular agent with favorable properties.
    • Despite its advantages, 99mTc MAG3's clearance is suboptimal compared to OIH.
    • Further research into N3S ligand modifications has not yet yielded a clinically superior agent.